Boston Scientific Corporation (NYSE:BSX) Set to Announce Earnings on Thursday

Boston Scientific Corporation (NYSE:BSX) is scheduled to post its quarterly earnings results before the market opens on Thursday, July 27th. Analysts expect Boston Scientific Corporation to post earnings of $0.31 per share for the quarter. Boston Scientific Corporation has set its Q2 guidance at $0.30-0.32 EPS and its FY17 guidance at $1.22-1.26 EPS.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by $0.01. Boston Scientific Corporation had a return on equity of 23.45% and a net margin of 5.07%. The business had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.08 billion. During the same period last year, the company posted $0.28 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts expect Boston Scientific Corporation to post $1.25 EPS for the current fiscal year and $1.39 EPS for the next fiscal year.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 27.93 on Thursday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51. The stock has a market capitalization of $38.25 billion, a PE ratio of 89.52 and a beta of 1.10. The company’s 50-day moving average is $27.74 and its 200-day moving average is $25.63.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, April 5th. JPMorgan Chase & Co. restated an “overweight” rating and set a $31.00 price target (up previously from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Royal Bank Of Canada restated a “buy” rating and set a $31.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. TheStreet upgraded shares of Boston Scientific Corporation from a “c+” rating to a “b” rating in a report on Tuesday, April 25th. Finally, Stifel Nicolaus raised their price target on shares of Boston Scientific Corporation from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, April 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $29.61.

TRADEMARK VIOLATION WARNING: This report was first posted by [[site]] and is the property of of [[site]]. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at [[permalink]].

In other news, SVP David A. Pierce sold 2,972 shares of Boston Scientific Corporation stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $27.70, for a total transaction of $82,324.40. Following the sale, the senior vice president now directly owns 28,572 shares in the company, valued at approximately $791,444.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael P. Phalen sold 34,773 shares of Boston Scientific Corporation stock in a transaction dated Wednesday, April 26th. The shares were sold at an average price of $26.00, for a total transaction of $904,098.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 243,579 shares of company stock worth $6,590,050. 0.74% of the stock is owned by company insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.